Ind-Swift Laboratories Limited has informed the Exchange about Conversion
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ind-Swift Laboratories has allotted 51,85,124 equity shares (face value ₹10 each) on conversion of an equal number of Fully Convertible Warrants that were originally issued on August 30, 2024 at ₹121 per share. The Preferential Issue Committee approved this on July 21, 2025, and the company received the balance subscription amount of about ₹47.06 crore. Of the total, Essix Biosciences (a promoter-group entity) received 7,00,000 shares, while non-promoter HCP Investments received 44,85,124 shares. Following this allotment, the company's paid-up equity share capital has risen to about ₹72.39 crore, divided into 7.24 crore equity shares.
This is a pre-committed conversion (warrants were issued in August 2024), so it brings in the remaining ~₹47 crore of capital without any fresh dilution surprise. Existing shareholders see a modest increase in share count and a slight reduction in their proportional holding, but the company's capital base is now stronger.